Related Experiment Video
Updated: Aug 24, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
PTEN regulates Mdm2 expression through the P1 promoter
Chun-Ju Chang1, Daniel J Freeman, Hong Wu
1Department of Molecular and Medical Pharmacology and Howard Hughes Medical Institute, University of California School of Medicine, Los Angeles, California 90095-1735, USA.
Abstract:
MDM2 is an oncoprotein that controls tumorigenesis through both p53-dependent and -independent mechanisms. Mdm2 mRNA level is transcriptionally regulated by p53 in response to stress such as DNA damage, and its protein level and subcellular localization are post-translationally modulated by the AKT serine/threonine kinase. Previous studies showed that PTEN, a dual specificity phosphatase that antagonizes phosphatidylinositol 3-kinase/AKT signaling, is capable of blocking MDM2 nuclear translocation and destabilizing the MDM2 protein. Results from our current study demonstrate an additional role for PTEN in regulating MDM2 functions; PTEN modulates Mdm2 transcription and isoform selection by negatively regulating its P1 promoter. In Pten-null cell lines and prostate cancer tissues, Mdm2 P1 promoter activity is up-regulated, resulting in increased L-Mdm2 expression and enhanced p90(MDM2) isoform production. Furthermore, PTEN controls Mdm2 P1 promoter activity through its lipid phosphatase activity, independent of p53. Thus, our results provide a novel mechanism for PTEN in controlling MDM2 oncoprotein functions.
Insights
Phosphatase and tensin homolog (PTEN) regulates the MDM2 oncoprotein by controlling its transcription and isoform selection via the P1 promoter. This discovery reveals a new mechanism for PTEN in managing MDM2 functions.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- MDM2 is an oncoprotein crucial for tumorigenesis, regulated by p53 and AKT signaling.
- PTEN antagonizes AKT signaling, previously shown to inhibit MDM2 nuclear translocation and protein stability.
- The precise mechanisms by which PTEN influences MDM2, particularly its transcriptional regulation and isoform expression, require further elucidation.
Purpose of the Study:
- To investigate the novel role of PTEN in regulating MDM2 transcription and isoform selection.
- To determine the impact of PTEN on MDM2 P1 promoter activity.
- To elucidate the mechanism by which PTEN controls MDM2 P1 promoter activity, including its dependence on p53 and lipid phosphatase activity.
Main Methods:
- Analysis of Mdm2 P1 promoter activity in Pten-null and wild-type cell lines.
- Assessment of L-Mdm2 expression and p90(MDM2) isoform production.
- Investigation of PTEN's lipid phosphatase activity in regulating Mdm2 P1 promoter activity.
- Evaluation of the p53-independent nature of PTEN's regulation of Mdm2 P1 promoter.
Main Results:
- PTEN negatively regulates Mdm2 P1 promoter activity.
- Pten-null cell lines and prostate cancer tissues exhibit up-regulated Mdm2 P1 promoter activity.
- This up-regulation leads to increased L-Mdm2 expression and enhanced p90(MDM2) isoform production.
- PTEN controls Mdm2 P1 promoter activity via its lipid phosphatase activity, independent of p53.
Conclusions:
- PTEN plays a novel role in modulating Mdm2 transcription and isoform selection by negatively regulating the Mdm2 P1 promoter.
- Loss of PTEN function results in increased Mdm2 P1 promoter activity, leading to higher levels of L-Mdm2 and p90(MDM2) isoforms.
- PTEN's regulation of Mdm2 P1 promoter activity is independent of p53 and relies on its lipid phosphatase function, offering a new perspective on PTEN's tumor-suppressive mechanisms.
Related Concept Videos
Abnormal Proliferation
Master Transcription Regulators
Negative Regulator Molecules
Cell Specific Gene Expression
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
